Long-term follow-up of a patient with papillary thyroid carcinoma, elevated thyroglobulin levels, and negative imaging studies

Endocrine Practice

Volumn 11, Issue 1, 2005, Pages 43-48

  Caplan, Robert H ^a,b   Wickus, Gary G ^a   Manske, Brian R ^a  

^a GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THYROGLOBULIN;

CANCER RECURRENCE; FOLLOW UP; HUMAN; PAPILLARY THYROID CARCINOMA; POSITRON EMISSION TOMOGRAPHY; REVIEW; THYROID CARCINOMA; THYROIDECTOMY; ARTICLE; BLOOD; CASE REPORT; CHILD; FEMALE; PAPILLARY CARCINOMA; PRESCHOOL CHILD; SCINTISCANNING; THYROID TUMOR; TIME; TUMOR RECURRENCE;

CARCINOMA, PAPILLARY; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; TIME FACTORS;

EID: 23644431542     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.11.1.43     Document Type: Review

References (29)

1. Ries LAG, Eisner MP, Kosary CI, et al. SEER Cancer Statistics Review, 1973-1997. Bethesda, MD: National Cancer Institute, 2000.
2. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447-1463.
3. Torréns JI, Burch HB. Serum thyroglobulin measurement: utility in clinical practice. Endocrinol Metab Clin North Am. 2001;30:429-467.
4. Schlumberger M, Arcangioli O, Piekarski JD, Tobiana M, Parmentier C. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest x-rays. J Nucl Med. 1988;29:1790-1794.
5. Pacini F, Lippi F, Formica N, et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med. 1987;28:1888-1891.
6. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab. 1995;80:1488-1492.
7. Schlumberger M, Mancusi F, Baudin E, Pacini F. 131I therapy for elevated thyroglobulin levels. Thyroid. 1997; 7:273-276.
8. Levy EG. Thyroglobulin-positive, radioiodine-negative thyroid cancer. Thyroid. 2001;11:599-602.
9. Sisson JC, Thompson NW, Giordano TJ, England BG, Normolle DP. Serum thyroglobulin levels after thyroxine withdrawal in patients with low risk papillary thyroid carcinoma. Thyroid. 2000;10:165-169.
10. McDougall IR. 1311 treatment of 1311 negative whole body scan, and positive thyroglobulin in differentiated thyroid carcinoma: what is being treated? Thyroid. 1997; 7:669-672.
11. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:1433-1441.
12. Cady B. Hayes Martin Lecture. Our AMES is true: how an old concept still hits the mark; or, risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer. Am J Surg. 1997;174:462-468.
13. Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyroglobulin assays. Clin Chem. 1996;42:164-173.
14. Preissner CM, O'Kane DJ, Singh RJ, Morris JC, Grebe SK. Phantoms in the test tube: heterophile antibody interferences in serum thyroglobulin assays. J Clin Endocrinol Metab. 2003;88:3069-3074.
15. Yativ N, Buskila D, Blank M, Burek CL, Rose NR, Shoenfeld Y. The detection of antithyroglobulin activity in human serum monoclonal immunoglobulins (monoclonal gammopathies). Immunol Res. 1993;12:330-337.
16. Lukinac L, Kusic Z, Kes P. False-positive titers of thyroid autoantibodies in patients undergoing hemodialysis [letter]? Clin Chem. 1991;37:2153-2154.
17. Spitzweg C, Joba W, Heufelder AE. Expression of thyroid-related genes in human thymus. Thyroid. 1999;9:133-141.
18. Spinner RJ, Moore KL, Gottfried MR, Lowe JE, Sabiston DC Jr. Thoracic intrathymic thyroid. Ann Surg. 1994;200:91-96.
19. Spencer CA, LoPresti JS, Fatemi S, Nicoloff JT. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid. 1999;9:435-441.
20. Pacini F, Agate L, Elisei R, et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab. 2001;86:4092-4097.
21. Pacini F, Molinaro E, Castagna MG, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:3668-3673.
22. Mazzaferri EL. Changing paradigms in the follow-up of patients with differentiated thyroid cancer: an alternative to [18F]fluorodeoxyglucose positron emission tomographic scanning. Endocr Pract. 2003;9:324-326.
23. Grünwald F, Kalicke T, Feine U, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med. 1999;26:1547-1552.
24. Chin BB, Patel P, Cohade C, Ewertz M, Wahl R, Ladenson P. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2004;89:91-95.
25. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989 [with discussion]. Surgery. 1993;114:1050-1058.
26. Zimmerman D, Hay ID, Gough IR, et al. Papillary thyroid carcinoma in children and adults: long-term follow-up of 1039 patients consecutively treated at one institution during three decades. Surgery. 1988;104:1157-1166.
27. Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab. 2003; 88:1107-1111.
28. Vickery AL Jr, Wang CA, Walker AM. Treatment of intrathyroidal papillary carcinoma of the thyroid. Cancer. 1987;60:2587-2595.
29. Thomas CG Jr. Thyroid cancer: treatment. In: Werner SG, Ingbar SH, eds. The Thyroid. 3rd ed. New York. NY: Harper & Row, 1971:456.